BeOne Medicines Statistics

Total Valuation

BeOne Medicines has a market cap or net worth of CNY 215.58 billion. The enterprise value is 204.66 billion.

Market Cap	215.58B
Enterprise Value	204.66B

Important Dates

The next estimated earnings date is Friday, August 1, 2025.

Earnings Date	Aug 1, 2025
Ex-Dividend Date	n/a

Share Statistics

Current Share Class	115.06M
Shares Outstanding	n/a
Shares Change (YoY)	+1.47%
Shares Change (QoQ)	+4.62%
Owned by Insiders (%)	n/a
Owned by Institutions (%)	n/a
Float	84.49M

Valuation Ratios

PE Ratio	n/a
Forward PE	98.61
PS Ratio	7.11
PB Ratio	8.49
P/TBV Ratio	8.61
P/FCF Ratio	n/a
P/OCF Ratio	140.12
PEG Ratio	n/a

Financial Ratio History

Enterprise Valuation

EV / Earnings	-71.88
EV / Sales	6.82
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	-156.28

Financial Position

The company has a current ratio of 1.96, with a Debt / Equity ratio of 0.28.

Current Ratio	1.96
Quick Ratio	1.64
Debt / Equity	0.28
Debt / EBITDA	n/a
Debt / FCF	-5.52
Interest Coverage	-15.99

Financial Efficiency

Return on equity (ROE) is -11.44% and return on invested capital (ROIC) is -4.16%.

Return on Equity (ROE)	-11.44%
Return on Assets (ROA)	-3.22%
Return on Invested Capital (ROIC)	-4.16%
Return on Capital Employed (ROCE)	-7.69%
Revenue Per Employee	2.75M
Profits Per Employee	-258,837
Employee Count	11,000
Asset Turnover	0.73
Inventory Turnover	1.35

Taxes

In the past 12 months, BeOne Medicines has paid 897.56 million in taxes.

Income Tax	897.56M
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has increased by +95.54% in the last 52 weeks. The beta is 0.30, so BeOne Medicines's price volatility has been lower than the market average.

Beta (5Y)	0.30
52-Week Price Change	+95.54%
50-Day Moving Average	239.09
200-Day Moving Average	195.51
Relative Strength Index (RSI)	52.39
Average Volume (20 Days)	2,992,986

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	4.57

Income Statement

In the last 12 months, BeOne Medicines had revenue of CNY 30.30 billion and -2.85 billion in losses. Loss per share was -26.87.

Revenue	30.30B
Gross Profit	25.70B
Operating Income	-2.15B
Pretax Income	-1.95B
Net Income	-2.85B
EBITDA	-885.34M
EBIT	-2.15B
Loss Per Share	-26.87

Full Income Statement

Balance Sheet

The company has 18.26 billion in cash and 7.23 billion in debt, giving a net cash position of 11.03 billion.

Cash & Cash Equivalents	18.26B
Total Debt	7.23B
Net Cash	11.03B
Net Cash Per Share	n/a
Equity (Book Value)	25.39B
Book Value Per Share	235.25
Working Capital	13.88B

Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was 1.54 billion and capital expenditures -2.85 billion, giving a free cash flow of -1.31 billion.

Operating Cash Flow	1.54B
Capital Expenditures	-2.85B
Free Cash Flow	-1.31B
FCF Per Share	n/a

Full Cash Flow Statement

Margins

Gross margin is 84.81%, with operating and profit margins of -7.10% and -9.40%.

Gross Margin	84.81%
Operating Margin	-7.10%
Pretax Margin	-6.43%
Profit Margin	-9.40%
EBITDA Margin	-2.92%
EBIT Margin	-7.10%
FCF Margin	n/a

Dividends & Yields

BeOne Medicines does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-1.47%
Shareholder Yield	n/a
Earnings Yield	-1.32%
FCF Yield	-0.61%

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value	n/a
Lynch Upside	n/a
Graham Number	n/a
Graham Upside	n/a

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

BeOne Medicines has an Altman Z-Score of 4.11 and a Piotroski F-Score of 5.

Altman Z-Score	4.11
Piotroski F-Score	5